Powering Next-Gen NK Cell Therapy with Non-Viral Delivery

On-Demand Webinar | Powering Next-Gen NK Cell Therapy with Non-Viral Delivery

Advancing cell therapy requires safer, scalable, and cost-efficient manufacturing strategies. This webcast will explore how CAR-NK cells are emerging as a powerful alternative to CAR-T therapies for multiple myeloma, targeting B-cell maturation antigen with improved safety and accessibility. Unlike CAR-T approaches, CAR-NK therapy offers an off-the-shelf solution without HLA matching and with reduced toxicity risk.

Join Dr. Chu from the University of Alberta’s Cross Cancer Institute as he showcases the results from high-throughput screening of anti-BCMA CAR constructs using an LNP-mediated mRNA delivery system. This non-viral approach enhances safety by avoiding insertional mutagenesis while enabling scalable, cost-effective manufacturing. Optimized mRNA encapsulation, combined with the GROW-NK soluble activator, achieved high transfection efficiency and strong BCMA-specific cytotoxicity in NK cells — without feeder cells.

Learn how innovative technologies, including LNP-mediated mRNA delivery system and NanoSpark^® feeder-free soluble activator, support the next generation of scalable CAR-NK development.

What You Will Learn:

Evaluate the feasibility of the non-viral approach for generating BCMA-directed CAR-NK cell therapies.
Understand strategies to optimize mRNA–LNP encapsulation to achieve high transfection efficiency in NK cells.
Assess the advantages of the soluble NK cell activator, including its impact on activation and cytotoxicity.

Clear form data

Please Complete the Form

First Name *

Last Name *

Email *

Phone Number *

Company *

Job Title *

Address *

Country *

Postal Code *

I would like to sign up for newsletters from Sartorius (Sartorius AG and its affiliated companies) based of my personal interests.
I can revoke my consent at any time with effect for the future by sending an e-mail to unsubscribe@sartorius.com or by clicking on the "unsubscribe" link in e-mails I have received.

* These fields are required Information on the use of your data can be found in our privacy policy

Complete Form to Watch

Michael Chu, MD

Medical Oncologist, Associate Professor, Cross Cancer Institute

Michael Chu, PhD is a clinician scientist at the Cross Cancer Institute. His research focuses on basic and translational cancer research with an emphasis on immune therapy, including monoclonal antibodies and cellular therapy. He has a wide range of clinical research where he serves as principal investigator and sub-principal investigator on multiple phase I, II, and III clinical trials.

Curtis Hodge, PhD

Co-Founder, CEO, Nanotein Technologies, Inc.

Curtis Hodge is the CEO and co-founder of Nanotein Technologies, Inc., a biotech company that develops NK and T cell reagents that address current limitations and streamline the production of cell therapies. Curtis led Nanotein to form an exclusive partnership with Sartorius to bring global access to these critically enabling next-gen reagents. 